BrightSpring Health Services reported higher third-quarter revenue and earnings from continuing operations, with growth in both its Pharmacy Solutions and Provider Services businesses. The company also raised its full-year 2026 revenue and Adjusted EBITDA guidance.
The results exclude Community Living, which BrightSpring sold on March 30, 2026. The company’s full-year outlook also excludes the effects of future acquisitions that have not yet closed.
Key details
- Third-quarter revenue rose 26.4% to $4.21 billion, from $3.33 billion a year earlier. Gross profit increased 32.3% to $519 million.
- Net income from continuing operations was $101 million, compared with $38 million in the year-earlier quarter.
- Adjusted EBITDA increased 42% to $228 million, from $160 million. Segment EBITDA rose 39% to $281 million; corporate costs were $53 million.
- Pharmacy Solutions revenue grew 26% to $3.73 billion. The business dispensed 10.95 million prescriptions, up 2%, while revenue per prescription rose 24% to $340.86 and gross profit per prescription increased 27% to $28.86.
- Provider Services revenue increased 31% to $481 million. Home Health Care’s average daily census rose 58% to 47,256. Rehab Care served 7,574 people, up 9%, while Personal Care served 16,320, up 1%.
- For the first nine months of 2026, revenue was $11.7 billion, up 25%, and Adjusted EBITDA was $623 million, up 44%. Pharmacy Solutions generated $10.31 billion in revenue, up 24%, and Provider Services generated $1.39 billion, up 30%.
- BrightSpring raised its 2026 revenue and Adjusted EBITDA guidance. Its total revenue target is $15.9 billion to $16.125 billion, representing growth of 23.2% to 24.9% from 2025 results excluding Community Living. The company also set a Pharmacy Solutions revenue range of $14 billion to $14.2 billion, or 22.3% to 24.0% growth.
- Leverage was 1.79 times at Sept. 30, down from 2.15 times at June 30.
What the results show
Both business segments contributed to quarterly growth, while prescription volume rose much more slowly than pharmacy revenue. The increase in revenue per prescription accompanied that difference. BrightSpring also reported a lower leverage ratio than at the end of the prior quarter.